{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:59:27Z","timestamp":1790963967240,"version":"4.1.0"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) is the second most common cause of cancer death globally. Recent clinical trials suggest an emerging role for HER2 as a potential clinically relevant biomarker in CRC. Testing for HER2 in CRC is not standard practice; consequently, the prevalence of HER2 positivity (HER2+) in patients with CRC remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature review and meta-analysis were conducted to generate estimates of proportions of patients with CRC with HER2 overexpression or HER2 amplification and HER2+ (either overexpression or amplification), overall and in patients with rat sarcoma virus (RAS) wild-type cancer. HER2+ was defined as 1) immunohistochemistry with a score of 3+, 2)\u00a0immunohistochemistry with a score of 2+ and in situ hybridization+, or 3) next-generation sequencing positive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 224 studies identified with information on HER2 in CRC, 52 studies used a US Food and Drug Administration\u2013approved assay and were selected for further analysis. Estimated HER2+ rate was 4.1% (95% confidence interval [CI]\u2009=\u20093.4% to 5.0%) overall (n\u2009=\u200917\u200a589). HER2+ rates were statistically higher in RAS wild-type (6.1%, 95% CI\u2009=\u20095.4% to 6.9%) vs RAS mutant CRC (1.1%, 95% CI\u2009=\u20090.3% to 4.4%; P\u00a0&amp;lt; .0001). Despite limited clinical information, we confirmed enrichment of HER2+ CRC in patients with microsatellite stable and left-sided CRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis provides an estimate of HER2+ CRC and confirms enrichment of HER2 in microsatellite stable, left-sided, RAS wild-type CRC tumors. Our work is important given the recently described clinical efficacy of HER2-targeted therapies in HER2+ CRC and informs strategies for incorporation of HER2 testing into standard of care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkad082","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T11:30:43Z","timestamp":1696937443000},"source":"Crossref","is-referenced-by-count":24,"title":["Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-2013","authenticated-orcid":false,"given":"Harshabad","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Gastrointestinal Cancers, Dana-Farber Cancer Institute , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Kang","sequence":"additional","affiliation":[{"name":"Curta , Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bloudek","sequence":"additional","affiliation":[{"name":"Curta , Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-I","family":"Hsu","sequence":"additional","affiliation":[{"name":"Seagen Inc. , Bothell, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Corinna Palanca-Wessels","sequence":"additional","affiliation":[{"name":"Seagen Inc. , Bothell, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stecher","sequence":"additional","affiliation":[{"name":"Seagen Inc. , Bothell, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Siadak","sequence":"additional","affiliation":[{"name":"Seagen Inc. , Bothell, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-1494","authenticated-orcid":false,"given":"Kimmie","family":"Ng","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Cancers, Dana-Farber Cancer Institute , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"2024012013314369900_pkad082-B1","author":"World Health Organization International Agency for Research on Cancer (IARC)"},{"issue":"3","key":"2024012013314369900_pkad082-B2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2024012013314369900_pkad082-B3","first-page":"89","article-title":"Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz Gastroenterol"},{"issue":"12","key":"2024012013314369900_pkad082-B4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","article-title":"Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies","volume":"16","author":"Keum","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"2024012013314369900_pkad082-B5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(19)30147-5","article-title":"Changes in colorectal cancer incidence in seven high-income countries: a population-based study","volume":"4","author":"Araghi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"2024012013314369900_pkad082-B6","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1136\/gutjnl-2019-319511","article-title":"Global patterns and trends in colorectal cancer incidence in young adults","volume":"68","author":"Siegel","year":"2019","journal-title":"Gut"},{"issue":"10","key":"2024012013314369900_pkad082-B7","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1136\/gutjnl-2018-317592","article-title":"Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years","volume":"68","author":"Vuik","year":"2019","journal-title":"Gut"},{"issue":"7","key":"2024012013314369900_pkad082-B8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"2024012013314369900_pkad082-B9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4251\/wjgo.v10.i7.145","article-title":"Novel biomarkers for patient stratification in colorectal cancer: a review of definitions, emerging concepts, and data","volume":"10","author":"Chand","year":"2018","journal-title":"World J Gastrointest Oncol"},{"issue":"10","key":"2024012013314369900_pkad082-B10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.4251\/wjgo.v13.i10.1288","article-title":"Molecular testing for colorectal cancer: clinical applications","volume":"13","author":"Imyanitov","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"2024012013314369900_pkad082-B11","year":"2022"},{"key":"2024012013314369900_pkad082-B12","author":". \u00a9 National Comprehensive Cancer Network","year":"2022"},{"issue":"1","key":"2024012013314369900_pkad082-B13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"19","key":"2024012013314369900_pkad082-B14","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1002\/cncr.33102","article-title":"Novel HER2-targeted therapies for HER2-positive metastatic breast cancer","volume":"126","author":"Kunte","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"2024012013314369900_pkad082-B15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2024012013314369900_pkad082-B16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"2024012013314369900_pkad082-B17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"2024012013314369900_pkad082-B18","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1002\/cncr.32392","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE","volume":"125","author":"Perez","year":"2019","journal-title":"Cancer"},{"issue":"9742","key":"2024012013314369900_pkad082-B19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"2024012013314369900_pkad082-B20","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod Pathol"},{"issue":"suppl 15","key":"2024012013314369900_pkad082-B21","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2021.39.15_suppl.3004","article-title":"MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors [abstract]","volume":"39","author":"Meric-Bernstam","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2024012013314369900_pkad082-B22","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/JCO.2021.39.15_suppl.3505","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01) (abstract)","volume":"39","author":"Yoshino","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2024012013314369900_pkad082-B23","doi-asserted-by":"crossref","first-page":"v199","DOI":"10.1093\/annonc\/mdz246.004","article-title":"526PD TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): a GOZILA sub-study (abstract)","volume":"30","author":"Nakamura","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"2024012013314369900_pkad082-B24","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","article-title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial","volume":"27","author":"Nakamura","year":"2021","journal-title":"Nat Med"},{"issue":"suppl 5","key":"2024012013314369900_pkad082-B25","doi-asserted-by":"crossref","first-page":"v200","DOI":"10.1093\/annonc\/mdz246.005","article-title":"527PD - Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial (abstract)","volume":"30","author":"Strickler","year":"2019","journal-title":"Ann Oncol"},{"key":"2024012013314369900_pkad082-B26","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.2147\/CMAR.S213247","article-title":"Comprehensive assessment of HER2 alteration in a colorectal cancer cohort: From next-generation sequencing to clinical significance","volume":"11","author":"Yeh","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"4","key":"2024012013314369900_pkad082-B27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neo.2015.03.004","article-title":"Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors","volume":"17","author":"Hovelson","year":"2015","journal-title":"Neoplasia"},{"issue":"6","key":"2024012013314369900_pkad082-B28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"11","key":"2024012013314369900_pkad082-B29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2024012013314369900_pkad082-B30","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2024012013314369900_pkad082-B31","first-page":"PO.18.00345","article-title":"Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications","volume":"3","author":"Dumbrava","year":"2019","journal-title":"J Clin Oncol Precis Oncol"},{"issue":"suppl 15","key":"2024012013314369900_pkad082-B32","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2020.38.15_suppl.4086","article-title":"Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB\/SWOG 80405 (Alliance)","volume":"38","author":"Battaglin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"28","key":"2024012013314369900_pkad082-B33","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.3748\/wjg.v22.i28.6345","article-title":"Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer","volume":"22","author":"Sforza","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"99","key":"2024012013314369900_pkad082-B34","doi-asserted-by":"crossref","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci Transl Med"},{"issue":"6","key":"2024012013314369900_pkad082-B35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov"},{"key":"2024012013314369900_pkad082-B36","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022)","author":"Higgins","year":"2022"},{"key":"2024012013314369900_pkad082-B37","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (Updated July 2019)","author":"Deeks","year":"2019"},{"key":"2024012013314369900_pkad082-B38","article-title":"Genomic assessment of blood-derived circulating tumor DNA in patients with colorectal cancers: correlation with tissue sequencing, therapeutic response, and survival","volume":"3","author":"Kato","year":"2019","journal-title":"J Clin Oncol Precis Oncol"},{"issue":"4","key":"2024012013314369900_pkad082-B39","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/PAS.0b013e318272ff4d","article-title":"Frequency of HER-2 positivity in rectal cancer and prognosis","volume":"37","author":"Conradi","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2024012013314369900_pkad082-B40","doi-asserted-by":"crossref","first-page":"16894","DOI":"10.1038\/s41598-019-53039-y","article-title":"Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients","volume":"9","author":"Dong","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"2024012013314369900_pkad082-B41","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/his.14158","article-title":"Molecular and clinicopathological features of colorectal adenocarcinoma with enteroblastic differentiation","volume":"77","author":"Yamashiro","year":"2020","journal-title":"Histopathology"},{"key":"2024012013314369900_pkad082-B42","doi-asserted-by":"crossref","first-page":"e8602","DOI":"10.7717\/peerj.8602","article-title":"HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China","volume":"8","author":"Zhang","year":"2020","journal-title":"PeerJ"},{"issue":"26","key":"2024012013314369900_pkad082-B43","doi-asserted-by":"crossref","first-page":"42198","DOI":"10.18632\/oncotarget.15030","article-title":"Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience","volume":"8","author":"Gong","year":"2017","journal-title":"Oncotarget"},{"key":"2024012013314369900_pkad082-B44","author":"Hechtman"},{"issue":"3","key":"2024012013314369900_pkad082-B45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clcc.2018.05.006","article-title":"Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer","volume":"17","author":"Sawada","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"suppl 13","key":"2024012013314369900_pkad082-B46","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/1538-7445.AM2017-4380","article-title":"4380: integrative genomics analysis of metastatic colorectal cancer [abstract]","volume":"77","author":"Lipsyc","year":"2017","journal-title":"Cancer Res"},{"key":"2024012013314369900_pkad082-B47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1200\/po.1219.00154","article-title":"International harmonization of provisional diagnostic criteria for ERBB2-amplified metastatic colorectal cancer allowing for screening by next-generation sequencing panel","volume":"4","author":"Fujii","year":"2020","journal-title":"J Clin Oncol Precis Oncol"},{"issue":"7","key":"2024012013314369900_pkad082-B48","first-page":"4454","article-title":"Immunohistochemical results of HER2\/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas","volume":"7","author":"Song","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"2024012013314369900_pkad082-B49","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00428-015-1747-2","article-title":"HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: Clinical relevance and prognostic value","volume":"466","author":"Seo","year":"2015","journal-title":"Virchows Arch"},{"issue":"4","key":"2024012013314369900_pkad082-B50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4251\/wjgo.v11.i4.335","article-title":"Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas","volume":"11","author":"Wang","year":"2019","journal-title":"World J Gastrointest Oncol"},{"issue":"4","key":"2024012013314369900_pkad082-B51","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.4143\/crt.2017.487","article-title":"Ligand-independent epidermal growth factor receptor overexpression correlates with poor prognosis in colorectal cancer","volume":"50","author":"Yun","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"suppl 4","key":"2024012013314369900_pkad082-B52","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/JCO.2019.37.4_suppl.604","article-title":"Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC)","volume":"37","author":"Raghav","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024012013314369900_pkad082-B53","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ijc.11137","article-title":"HER 2\/neu expression and gene amplification in colon cancer","volume":"105","author":"Nathanson","year":"2003","journal-title":"Int J Cancer"},{"issue":"12","key":"2024012013314369900_pkad082-B54","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/annonc\/mdt408","article-title":"HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab","volume":"24","author":"Sclafani","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"2024012013314369900_pkad082-B55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/07357907.2018.1439054","article-title":"Membranous or cytoplasmic HER2 expression in colorectal carcinoma: evaluation of prognostic value using both IHC & BDISH","volume":"36","author":"Buhmeida","year":"2018","journal-title":"Cancer Invest"},{"issue":"3","key":"2024012013314369900_pkad082-B56","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1158\/1541-7786.MCR-15-0392-T","article-title":"Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS\/RAF","volume":"14","author":"Hechtman","year":"2016","journal-title":"Mol Cancer Res"},{"key":"2024012013314369900_pkad082-B57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-1","article-title":"Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?","volume":"9","author":"Kavanagh","year":"2009","journal-title":"BMC Cancer"},{"issue":"4","key":"2024012013314369900_pkad082-B58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00428-018-2409-y","article-title":"HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features","volume":"473","author":"Park","year":"2018","journal-title":"Virchows Arch"},{"issue":"4","key":"2024012013314369900_pkad082-B59","first-page":"1287","article-title":"Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma","volume":"30","author":"Ramieri","year":"2010","journal-title":"Anticancer Res"},{"issue":"7","key":"2024012013314369900_pkad082-B60","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cncr.31125","article-title":"Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3","volume":"124","author":"Ross","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"2024012013314369900_pkad082-B61","doi-asserted-by":"crossref","first-page":"e98528","DOI":"10.1371\/journal.pone.0098528","article-title":"HER2 status in colorectal cancer: Its clinical significance and the relationship between HER2 gene amplification and expression","volume":"9","author":"Seo","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"2024012013314369900_pkad082-B62","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1634\/theoncologist.2018-0785","article-title":"HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer","volume":"24","author":"Sartore-Bianchi","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"2024012013314369900_pkad082-B63","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clcc.2020.11.002","article-title":"Prognostic value and molecular landscape of HER2 low-expressing metastatic colorectal cancer","volume":"20","author":"Yagisawa","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"2024012013314369900_pkad082-B64","doi-asserted-by":"crossref","first-page":"e000911","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO Open"},{"issue":"suppl 15","key":"2024012013314369900_pkad082-B65","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1200\/JCO.2019.37.15_suppl.3528","article-title":"Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA [abstract]","volume":"37","author":"Nakamura","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024012013314369900_pkad082-B66","first-page":"1","article-title":"Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer","volume":"3","author":"Raghav","year":"2019","journal-title":"J Clin Oncol Precis Oncol"},{"issue":"7","key":"2024012013314369900_pkad082-B67","doi-asserted-by":"crossref","first-page":"e1161","DOI":"10.1002\/onco.13786","article-title":"Relationship of HER2 alteration and microsatellite instability status in colorectal adenocarcinoma","volume":"26","author":"Qiu","year":"2021","journal-title":"Oncologist"},{"issue":"19","key":"2024012013314369900_pkad082-B68","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.3748\/wjg.v20.i19.5889","article-title":"Frequency of HER2\/neu overexpression in adenocarcinoma of the gastrointestinal system","volume":"20","author":"Farzand","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2024012013314369900_pkad082-B69","doi-asserted-by":"crossref","first-page":"e5700","DOI":"10.5812\/ijcm.5700","article-title":"Immunohistochemical study of HER2\/neu expression in colorectal cancer and its relation to other clinicopathological criteria and prognostic factors","volume":"10","author":"Sayadnejad","year":"2017","journal-title":"Int J Cancer Manag"},{"issue":"2","key":"2024012013314369900_pkad082-B70","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s11033-010-0232-x","article-title":"KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer","volume":"38","author":"Herreros-Villanueva","year":"2011","journal-title":"Mol Biol Rep"},{"issue":"5","key":"2024012013314369900_pkad082-B71","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00384-006-0192-8","article-title":"HER-2\/neu overexpression is an independent prognostic factor in colorectal cancer","volume":"22","author":"Park","year":"2007","journal-title":"Int J Colorectal Dis"},{"issue":"10","key":"2024012013314369900_pkad082-B72","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/bjc.2014.483","article-title":"HER2\/neu testing in primary colorectal carcinoma","volume":"111","author":"Ingold Heppner","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"2024012013314369900_pkad082-B73","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/path.4679","article-title":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","volume":"238","author":"Richman","year":"2016","journal-title":"J Pathol"},{"issue":"suppl 6","key":"2024012013314369900_pkad082-B74","first-page":"VI151","article-title":"ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8) [abstract]","volume":"27","author":"Laurent-Puig","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"2024012013314369900_pkad082-B75","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024012013314369900_pkad082-B76","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"2024012013314369900_pkad082-B77","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1152\/physiolgenomics.00185.2006","article-title":"Map of differential transcript expression in the normal human large intestine","volume":"33","author":"LaPointe","year":"2008","journal-title":"Physiol Genomics"},{"issue":"suppl 13","key":"2024012013314369900_pkad082-B78","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1158\/1538-7445.AM2018-4333","article-title":"4333: High incidence of ERBB2 amplification associated with microsatellite stable status in Chinese colorectal cancer patients [abstract]","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res"},{"issue":"3","key":"2024012013314369900_pkad082-B79","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2019-0441","article-title":"Guardant360 circulating tumor DNA assay is concordant with FoundationOne next-generation sequencing in detecting actionable driver mutations in anti-EGFR naive metastatic colorectal cancer","volume":"25","author":"Gupta","year":"2020","journal-title":"Oncologist"},{"issue":"12","key":"2024012013314369900_pkad082-B80","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41416-018-0293-5","article-title":"Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer","volume":"119","author":"Garc\u00eda-Foncillas","year":"2018","journal-title":"Br J Cancer"},{"issue":"8","key":"2024012013314369900_pkad082-B81","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/2159-8290.CD-14-1211","article-title":"HER2 activating mutations are targets for colorectal cancer treatment","volume":"5","author":"Kavuri","year":"2015","journal-title":"Cancer Discov"},{"issue":"5","key":"2024012013314369900_pkad082-B82","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov"},{"issue":"3","key":"2024012013314369900_pkad082-B83","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2024012013314369900_pkad082-B84","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkad082\/51990562\/pkad082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/8\/1\/pkad082\/56261788\/pkad082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/8\/1\/pkad082\/56261788\/pkad082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T08:33:26Z","timestamp":1705739606000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkad082\/7303866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkad082","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2023,10,10]]},"article-number":"pkad082"}}